Skip to content

Study · Animal study (in vivo) · sheep · 1997

3 results

Effects of neurohypophyseal hormone analogues on blood clotting factor VIII and fibrinolytic activity in sheep.

Neuenschwander S, Pliska V

European journal of pharmacology1 Apr 1997Cited by 4 (Europe PMC)

PMID9128840 (opens in a new tab)DOI10.1016/s0014-2999(97)00036-8 (opens in a new tab)PepBankPUB-09128840
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In sheep, oxytocin had a low potency for raising blood clotting factor VIII.

    In plain wordsIn sheep, oxytocin raised blood clotting factor VIII only weakly.

    Peptide
    Oxytocin
    Outcome
    IncreaseFactor VIII enhancing potency
    Study

    sheepn: not reported in source

    in vivo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Oxytocin and its highly selective uterotonic analogue, [Thr4,Gly7]oxytocin, displayed low antihaemophilic, and virtually no plasminogen activating potencies.
    1 context sentence
    Summary · context
    The increase in blood clotting factor VIII (antihaemophilic factor, F-VIII) and fibrinolytic activity induced by the administration of neurohypophyseal hormone analogues, was assayed in sheep.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In sheep, oxytocin had virtually no plasminogen activating potency.

    In plain wordsIn sheep, oxytocin hardly raised the blood's clot-dissolving activity.

    Peptide
    Oxytocin
    Outcome
    No significant changePlasminogen activator (fibrinolytic) activity
    Study

    sheepn: not reported in source

    in vivo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Oxytocin and its highly selective uterotonic analogue, [Thr4,Gly7]oxytocin, displayed low antihaemophilic, and virtually no plasminogen activating potencies.
    1 context sentence
    Summary · context
    The increase in blood clotting factor VIII (antihaemophilic factor, F-VIII) and fibrinolytic activity induced by the administration of neurohypophyseal hormone analogues, was assayed in sheep.

Studies that did not test the peptide alone1

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 03AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism

    In sheep, administration of the neurohypophyseal peptide analogues as a group decreased haematocrit and total plasma protein concentration shortly after dosing.

    In plain wordsIn sheep, a group of oxytocin and vasopressin analogues lowered the packed cell volume and plasma protein shortly after dosing.

    Peptide
    Oxytocin
    Outcome
    DecreaseHaematocrit and total plasma protein after peptide administration
    Study

    sheepn: not reported in source

    in vivo
    Outcome group
    Bleeding and clotting · Cardiovascular

    Source sentences

    Summary
    Strong decreases of the packed cell volume (haematocrit) and somewhat lower decreases of the total plasma protein concentration were observed shortly after administration of the peptides.
    1 context sentence
    Summary · context
    The increase in blood clotting factor VIII (antihaemophilic factor, F-VIII) and fibrinolytic activity induced by the administration of neurohypophyseal hormone analogues, was assayed in sheep.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

WithdrawnNot applicableNCT02063568

The Use of Thromboelastometry (ROTEM) to Evaluate the Changes in Coagulation With Two Different Doses of Oxytocin Following Cesarean Delivery

Duke Universityn = 0Jan 2015 to Dec 2015

Coagulation Changes With Oxytocin

Trial pageClinicalTrials.govUpdated 16 Dec 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:52 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.